Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

Alvotech Ordinary Shares

Bioventure is a UAE-based biopharmaceutical company focused on biotech and pharmaceutical activities, including the distribution and commercialization of biosimilars and targeted generic pharmaceuticals in the Middle East and Africa.

Bioventure

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Alvotech

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

Fuji Pharma

Shinhan Capital

Alvogen

Athos Capital

Aztiq

Aztiq Pharma

Baxter Ventures

Happy International Day of Women and Girls in Science! Women and girls represent half of the world’s population, but remain underrepresented in Science, Technology, Engineering and Mathematics, the STEM fields. Alvotech has achieved and strives to maintain gender balance in its workforce. Diversity increases the pool of talent , brings in fresh perspectives, and creativity. #womeninscience #equality #diversity #STEM

We are so happy to announce that Tanya Zharov, Alvotech’s Chief Legal Counsel, has been awarded the Icelandic Association of Businesswomen’s (FKA) highest honor, in recognition of extraordinary personal achievement and acts of inspiration for other women.

Congratulations also to the recipients of FKA's encouragement and gratitude awards, Inga Tinna Sigurðardóttir, founder of Dineout and Guðlaug Rakel Guðjónsdóttir, Managing Director of Sudurnes Hospital & Health Center. #FKA #WomenInBusiness

We are thrilled to receive European marketing authorization for our ustekinumab biosimilar, which will be marketed by STADA Group in Europe. This is the first ustekinumab biosimilar to be approved by the European Commission. Previously, the biosimilar was also approved in Canada and Japan. We're excited about spearheading biosimilar competition in the ustekinumab market and increasing patient access to biologic therapies! #biosimilars #HealthAccess https://ow.ly/Q50B50QpwCK

Ready for another whirlwind ride around the sun? After this extraordinary year, we can hardly wait! #366days #NewYear #2024

Snow in Reykjavik , the aroma of hot chocolate ☕ and Yule songs 🎅 filling the air. Today's winter solstice heralds longer days. May your holidays be merry and bright.🎄

Metric
Company Name	Alvotech Ordinary Shares	Bioventure
Symbol	ALVO
MSH ID	COM:ALVOTECH	AE:BIOVENTURE
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Biopharmaceuticals
Country	US	AE
Stage
Employee Count	999
Website	alvotech.com	bioventure.ae
LinkedIn		bioventure-fzc
Founders

Metric
Market Cap	3.61B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	91.43M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-69.42M
EBITDA	-334.64M
Operating Income	-354.86M
Net Income	-551.73M
EPS	-2.43
Diluted EPS	-2.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.15
Operating Profit Margin	-2.13
EBITDA Margin	-3.66
Net Profit Margin	-4.51
Return on Equity	1.01
Return on Assets	-0.47
Return on Capital Employed	2.18

COM:ALVOTECH

Alvotech

Last Close

12.44

22/11 21:00

Market Cap

3.65B

Beta: -

Volume Today

74.08K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-5.85
P/B Ratio	-5.28
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	63.72
EV Multiple	-7.19

Metric
Days Sales Outstanding	247.94
Days Payables Outstanding	144.34
Days Inventory Outstanding	237.56
Operating Cycle	636.99
Cash Conversion Cycle	501.79
Asset Turnover	0.13

Metric
Operating Cash Flow	-312.19M
Free Cash Flow	-358.66M
Cash Flow to Debt	-0.29
Operating Cash Flow/Sales	-2.26
Free Cash Flow Yield	-0.09

Metric
Cash & Equivalents	11.16M
Accounts Receivable	-8.32M
Inventory	74.43M
Goodwill	12.06M
Debt to Capitalization	7.52
Debt to Assets	1.06
Current Ratio	1.22
Quick Ratio	0.81

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-0.05
R&D to Revenue	3.24
SG&A to Revenue	1.43